**** I took this from an excellent contributor on the PTX forum...

**** I took this from an excellent contributor on the PTX forum (with thanks), but it’s obviously very telling that a pre-clinical asset can be bought out for almost 50% more than our current market cap, which of course includes $60m cash) ****

Roche has acquired Good Therapeutics US$250m (A$370m) cash and the biotech's shareholders will also be eligible for future (undisclosed) development, regulatory and commercial milestone payments.

Good Therapeutics has progressed from inception 6 years ago with venture capital backing of just US$30m.

The focus of Roche’s acquisition of Good Therapeutics is the biotech’s most advanced project, a preclinical cancer therapy designed to make the multiple current PD-1 targeting cancer therapeutics, such as Keytruda and Opdivo, benefit more patients. Its therapy is designed to deliver potent IL-2 stimulation of T cells without the toxicity that can limit unregulated IL-2 therapeutics.

https://www.statnews.com/2022/09/07...-preclinical-cancer-therapy/?utm_campaign=rss

https://www.fiercebiotech.com/biote...hape-shifting-program-250m-skys-limit-spinout